Literature DB >> 29685593

Routine immunization services costs and financing in China, 2015.

Wenzhou Yu1, Ming Lu2, Huaqing Wang1, Lance Rodewald3, Saisai Ji1, Chao Ma1, Yixing Li1, Jingshan Zheng1, Yifan Song1, Miao Wang1, Yamin Wang1, Dan Wu1, Lei Cao1, Chunxiang Fan1, Xuan Zhang1, Yanmin Liu4.   

Abstract

OBJECTIVE: To estimate the costs of routine immunization (RI) services in China in 2015, to provide objective data relevant to investment in the Expanded Program on Immunization, and to contribute to global data on costing and financing of RI.
METHODS: The study was conducted between January and March 2016. We selected 276 villages, 138 townships, 46 counties, and 40 prefectures from 15 provinces as investigation sites at random, stratified by eastern, middle, and western regions. Direct cost items included vaccines, personnel, cold chain, surveillance, communication, training, and supervision at the national, provincial, prefecture, county, township, and village levels. We obtained financial data from governmental and external sources. Indirect costs of RI included parents' transportation costs and productivity lost due to taking their children for vaccination.
RESULTS: Total direct costs were $92.42 for each child fully immunized ($4.20/dose), which equates to $1529.55 million per birth cohort. RI costs were higher in the eastern region than in the western region, and higher than that of the central region. Vaccination coverage was positively associated with direct routine immunization costs. The cost of the recommended vaccines was $19.08/child and vaccine only accounted for 20.64% of total costs. Operational cost, including surveillance, communication, training and supervision, was $217.31/child, accounting for 14.21% of total cost. The indirect cost per child was $72.86; the total indirect cost was $1205.83 million for the birth cohort. Government investment in RI accounted for about 70% of total costs. Revenue from sales of private-sector vaccine supported the remaining 30% of RI costs.
CONCLUSIONS: While government financing has increased, some operating costs continue to be provided from revenue generated by sales of Category 2 (private-sector) vaccines to families. China could benefit from bringing new and underutilized vaccines into the EPI system based on evidence that includes routine immunization vaccine and operations costs.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  China; Cost; Financing; Routine immunization

Mesh:

Year:  2018        PMID: 29685593     DOI: 10.1016/j.vaccine.2018.04.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Assessing vaccination coverage, timeliness, and its temporal variations among children in a rural area in China.

Authors:  Yangni He; Yang Liu; Bingbing Dai; Liang Zhao; Jiqun Lin; Juan Yang; Hongjie Yu
Journal:  Hum Vaccin Immunother       Date:  2020-07-09       Impact factor: 3.452

2.  Review of the status and challenges associated with increasing influenza vaccination coverage among pregnant women in China.

Authors:  Suizan Zhou; Carolyn M Greene; Ying Song; Ran Zhang; Lance E Rodewald; Luzhao Feng; Alexander J Millman
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452

3.  Measles vaccination of young infants in China: A cost-effectiveness analysis.

Authors:  Cara Bess Janusz; Abram L Wagner; Nina B Masters; Yaxing Ding; Ying Zhang; David W Hutton; Matthew L Boulton
Journal:  Vaccine       Date:  2020-05-22       Impact factor: 3.641

4.  Health and economic costs of an import-initiated measles outbreak in an international border area of Yunnan Province.

Authors:  Rongrong Zhou; Liqun Li; Shuyi Yuan; Jie Yin; Qiongfen Li; Licun Guo; Mengtian Li; Zhixian Zhao; Zhizhong Song
Journal:  Hum Vaccin Immunother       Date:  2020-09-29       Impact factor: 3.452

5.  Vaccine-preventable disease control in the People's Republic of China: 1949-2016.

Authors:  Wenzhou Yu; Lisa A Lee; Yanmin Liu; Robert W Scherpbier; Ning Wen; Guomin Zhang; Xu Zhu; Guijun Ning; Fuzhen Wang; Yixing Li; Lixin Hao; Xuan Zhang; Huaqing Wang
Journal:  Vaccine       Date:  2018-11-26       Impact factor: 3.641

6.  Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study.

Authors:  Changfa Xia; Xiaoqian Xu; Xuelian Zhao; Shangying Hu; Youlin Qiao; Yong Zhang; Raymond Hutubessy; Partha Basu; Nathalie Broutet; Mark Jit; Fanghui Zhao
Journal:  BMC Med       Date:  2021-03-03       Impact factor: 8.775

7.  Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis.

Authors:  Chathika Krishan Weerasuriya; Rebecca Claire Harris; Matthew Quaife; Christopher Finn McQuaid; Richard G White; Gabriela B Gomez
Journal:  Vaccines (Basel)       Date:  2021-03-11

8.  The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.

Authors:  Gabriela B Gomez; Richard G White; Chathika K Weerasuriya; Rebecca C Harris; C Finn McQuaid; Fiammetta Bozzani; Yunzhou Ruan; Renzhong Li; Tao Li; Kirankumar Rade; Raghuram Rao; Ann M Ginsberg
Journal:  BMC Med       Date:  2021-02-26       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.